Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis

Ping Yuan, Pu Ai, Yihan Liu, Zisheng Ai, Yi Wang, Weijun Cao, Xiaohuan Xia, Jialin C. Zheng
doi: https://doi.org/10.1101/2020.11.03.20224998
Ping Yuan
1Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People’s Hospital affiliated to Tongji University School of Medicine, Shanghai 200072, China
2Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai 200433, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pu Ai
1Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People’s Hospital affiliated to Tongji University School of Medicine, Shanghai 200072, China
3Wuxi Clinical College of Anhui Medical University, Hefei 230022, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yihan Liu
2Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai 200433, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zisheng Ai
4Department of Medical Statistics, Tongji University School of Medicine, Shanghai 200092, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Wang
1Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People’s Hospital affiliated to Tongji University School of Medicine, Shanghai 200072, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weijun Cao
2Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai 200433, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaohuan Xia
1Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People’s Hospital affiliated to Tongji University School of Medicine, Shanghai 200072, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jialinzheng{at}tongji.edu.cn xiaohuan_xia1{at}163.com
Jialin C. Zheng
1Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People’s Hospital affiliated to Tongji University School of Medicine, Shanghai 200072, China
5Collaborative Innovation Center for Brain Science, Tongji University, Shanghai 200092, China
6Departments of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198-5930, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jialinzheng{at}tongji.edu.cn xiaohuan_xia1{at}163.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

We aimed to summarize reliable medical evidence by the meta-analysis of all published clinical trials that investigated the safety, tolerability, and immunogenicity of vaccine candidates against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The PubMed, Cochrane Library, EMBASE, and medRxiv databases were used to select the studies. 7094 articles were identified initially and 43 were retrieved for more detailed evaluation. 5 randomized, double-blind, placebo-controlled trials were selected. A total of 1604 subjects with either vaccines or placebo infections were included in the meta-analysis within the scope of these articles. According to the results, there is an increase in total adverse events for subjects with either low (95% CI: 1.90-4.29) or high (CI: 2.65-5.63) dose vaccination. The adverse effects of COVID-19 vaccine are mainly local ones including pain, itching, and redness, and no significant difference was identified in the systemic reactions. All adverse effects were transient and resolved within a few days. Moreover, the neutralizing and IgG antibody levels post different dose vaccinations were all significantly increased at day 14/21 (P = 0.0004 and P = 0.0003, respectively) and day 28/35 (P < 0.00001) in vaccine groups compared to placebo controls. Besides, the levels of neutralizing and IgG antibodies were also elevated significantly at from day 14 to 35, versus day 0 (All P < 0.001). In conclusion, our analysis suggests that the current COVID-19 vaccine candidates are safe, tolerated, and immunogenic, which provides important information for further development, evaluation, and clinical application of COVID-19 vaccine.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported in part by research grants from the Major Research plan of the National Natural Science Foundation of China (No. 91949204 to J.C.Z.), the State Key Program of the National Natural Science Foundation of China (No. 81830037 to J.C.Z.), the National Basic Research Program of China (973 Program Grant No. 2014CB965001 to J.C.Z.), the National Institutes of Health (1R01NS097195-01 to J.C.Z.), the National Natural Science Foundation of China (No. 81901333 to X.X.), and Shanghai Sailing Program (No. 19YF1451700 to X.X.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The manuscript is a meta-analysis that does not require approval of the IRB.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All datasets generated for this study are included in the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted November 04, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
Ping Yuan, Pu Ai, Yihan Liu, Zisheng Ai, Yi Wang, Weijun Cao, Xiaohuan Xia, Jialin C. Zheng
medRxiv 2020.11.03.20224998; doi: https://doi.org/10.1101/2020.11.03.20224998
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
Ping Yuan, Pu Ai, Yihan Liu, Zisheng Ai, Yi Wang, Weijun Cao, Xiaohuan Xia, Jialin C. Zheng
medRxiv 2020.11.03.20224998; doi: https://doi.org/10.1101/2020.11.03.20224998

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (760)
  • Anesthesia (222)
  • Cardiovascular Medicine (3316)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (480)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13403)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5182)
  • Geriatric Medicine (483)
  • Health Economics (786)
  • Health Informatics (3286)
  • Health Policy (1146)
  • Health Systems and Quality Improvement (1199)
  • Hematology (432)
  • HIV/AIDS (1024)
  • Infectious Diseases (except HIV/AIDS) (14657)
  • Intensive Care and Critical Care Medicine (917)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (526)
  • Neurology (4957)
  • Nursing (263)
  • Nutrition (735)
  • Obstetrics and Gynecology (889)
  • Occupational and Environmental Health (797)
  • Oncology (2531)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1308)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (559)
  • Psychiatry and Clinical Psychology (4225)
  • Public and Global Health (7526)
  • Radiology and Imaging (1717)
  • Rehabilitation Medicine and Physical Therapy (1022)
  • Respiratory Medicine (982)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (73)
  • Transplantation (237)
  • Urology (206)